KDC-MN-138 – Kodiac biolabs

Plain-language summaryIntrigue 86 / 100

Kisspeptin is a hypothalamic neuropeptide that triggers GnRH release. It is the master regulator of puberty and reproductive hormones. Investigated for anovulatory infertility, hypogonadism, and reproductive disorders. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

58/100

Canonical KISS1R probe with strong human translation but limited novelty after two decades of characterization

Kisspeptin’s story starts in 2003, when loss-of-function KISS1 mutations were identified as the cause of idiopathic hypogonadotropic hypogonadism. That was genuinely exciting science. A single neuropeptide turned out to be the master switch for GnRH neuron firing, controlling puberty onset, menstrual cyclicity, the whole reproductive axis. The mechanism is clean and the biology is unambiguous: KISS1R agonism drives pulsatile GnRH release, which drives LH and FSH, which drives gonadal function. We like that story a lot.

What we dont like, from a research-merit standpoint, is that this story is now over 20 years old. The Cambridge group and others have done extensive characterization. Multiple groups have replicated the GnRH axis response across populations and experimental conditions. The mechanism is not in dispute. Thats actually the problem for novelty scoring. When the mechanism is settled and the primary application is the obvious one, you’re not on the frontier anymore.

Where kisspeptin remains genuinely useful is as a research tool for studying GnRH neuron dynamics. If your program involves hypothalamic neuroendocrinology, including puberty timing, functional hypothalamic amenorrhea, or energy-sensing crosstalk with the reproductive axis, kisspeptin is the canonical probe. There’s no replacement for it in that role. The kisspeptin-10 fragment is particularly useful for controlled, short-duration axis stimulation experiments where you want a tight pharmacokinetic window.

The fertility application is real and worth knowing. Several groups, including the London group with Lim et al. leading much of the clinical work, have explored kisspeptin-54 as an ovulation trigger in IVF. The OHSS-reduction angle has genuine rationale: because kisspeptin acts upstream through endogenous GnRH rather than exogenous LH, there’s a theoretical and some empirical advantage in high-responder populations. Effect size is real in the published trials. But we’re looking at phase 2 data, modest N, and a therapeutic problem that already has multiple established solutions. A phase 3 program is what’s needed to move this forward, and thats not there yet.

The emerging data on extrareproductive kisspeptin signaling, including metabolic effects, mood, and some interesting fMRI work on social bonding responses, adds a layer of interest. But these are exploratory signals, not yet a research program most labs would build around kisspeptin specifically. Honestly, this scores where it does because it’s a real neuropeptide with well-replicated human pharmacology and solid probe value in its domain, but the primary biology is settled and the clinical development path is narrow.

Novelty: 45
Mechanism promise: 55
In-category differentiation: 65
Evidence quality: 60
Translational signal: 65
Research bench value: 65

Rationale Kisspeptin is the master upstream regulator of the GnRH axis with well-replicated human pharmacology, scoring solidly on differentiation and translational signal as the canonical KISS1R probe; novelty is genuinely low after 20 years of active characterization, pulling the overall into the established-active tier rather than the frontier.

Hypothalamic neuropeptide / KISS1R agonist

An endogenous neuropeptide encoded by the KISS1 gene, master regulator of GnRH neuron firing and reproductive function.

Abstract

Kisspeptin (kisspeptin-54 and shorter active fragments including kisspeptin-10; encoded by the KISS1 gene) is an endogenous peptide identified in 2003 as the master regulator of GnRH neuron firing in the hypothalamus, controlling reproductive function and pubertal onset. Loss-of-function mutations in KISS1 or its receptor KISS1R produce hypogonadotropic hypogonadism. Exogenous kisspeptin administration stimulates LH and FSH release through GnRH neuron activation. The compound has been studied as a fertility therapeutic (induction of ovulation in functional hypothalamic amenorrhea) and as a research probe for reproductive neuroendocrine function. Pharmacokinetics: plasma half-life of kisspeptin-54 is ~30 minutes; kisspeptin-10 has shorter half-life. Research doses are highly variable; clinical trial doses range 0.01 to 6.4 nmol/kg IV.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-138Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-138

Kisspeptin

Abstract

Read the full monograph